Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Chemicalon Dec 10, 2020 10:40am
227 Views
Post# 32076362

some updates / only mind games

some updates / only mind games
Marketer of the Year: Unilever / Dec. 9, 2020
https://www.marketingdive.com/news/marketer-of-year-unilever-2020/589039/
 
"Last summer, Unilever committed to removing phrases like "whitening" from
its products while rebranding its Fair & Lovely of skin-lightening cosmetics."
 
---
 
What to know about dark knees / December 9, 2020
https://www.medicalnewstoday.com/articles/dark-knees#contacting-a-doctor
 
"However, if a person wants to try lightening their knees for aesthetic reasons,
they can try several different methods to treat their pigmentation at home."
 
---
 
Fairly Unfair: Skin Lightening in the Modern Era / December 9, 2020
https://www.northeasttoday.in/2020/12/09/fairly-unfair-skin-lightening-in-the-modern-era/
 
"There are alarming rates of skin lightening in India. In one study, all 4368 patients who
visited the dermatology department of an Indian hospital reported adverse effects of skin
lightening which indicates their use or misuse of skin lighteners."
 
---
 
First SGLT2 approved for heart condition / 10 Dec 2020
https://www1.racgp.org.au/newsgp/clinical/first-sglt2-approved-for-heart-condition
 
"Dapagliflozin (sold as Forxiga) has been extended to include the treatment of symptomatic
heart failure with reduced ejection fraction (systolic heart failure) in adults, as an
addition to the current standard of care."
 
---
 
Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.
https://www.hcplive.com/view/giorgino-diabetes-treatment-sglt2-inhibitors
 
"A major breakthrough in diabetes treatment in the last few years has been the advent of SGLT2 inhibitors"
 
---
 
Associations among circulating sphingolipids, β-cell function, and risk of developing type 2 diabetes: A population-based cohort study in China
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003451
 
"Though diabetes affects approximately 8.3% of the world population, a large fraction of patients is undiagnosed, accounting for 21.4% out
of 34.1 million and 63.5% out of 114.4 million American and Chinese adult diabetes cases"
 
--- only mind games, my favorite for the big deal
 
Boehringer Ingelheim invests to further develop the pet care market in China / September 29, 2020 
https://www.boehringer-ingelheim.com/press-release/partnership-further-develop-pet-market-china
 
"China’s pet market is one of thefastest growing markets in the world."
 
Boehringer Ingelheim Creates New China External Innovation Hub / 20.07.2020
https://pharmaboardroom.com/articles/boehringer-ingelheim-creates-new-china-rd-hub/
 
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance / 1 January 2020
https://www.boehringer-ingelheim.com/press-release/new-focus-boehringer-ingelheim-and-lilly-alliance
 
Milestone for Biopharmaceuticals in China / December 30th, 2019
https://www.boehringer-ingelheim.com/press-release/biopharmaceuticals-china
 
Boehringer Ingelheim Biopharmaceuticals China expands commercial manufacturing capacities / January 17, 2019
https://www.boehringer-ingelheim.com/press-release/capacityexpansionoasis
<< Previous
Bullboard Posts
Next >>